Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy (ExCell)

This study is currently recruiting participants.
Information provided by Gamida Cell -Teva Joint Venture Ltd.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Hematologic Malignancies
			Acute Myeloid Leukemia
			Lymphoid Leukemia
			Chronic Myeloid Leukemia
			Hodgkin's Disease
			Non-Hodgkin's Lymphoma
			Myelodysplastic Syndromes
2		Additional conditions recognized in this trial
			Hematologic Neoplasms
			Hodgkin Disease
			Leukemia
			Leukemia, Lymphoid
			Leukemia, Myelogenous, Chronic, BCR-ABL Positive
			Leukemia, Myeloid
			Leukemia, Myeloid, Acute
			Lymphoma
			Lymphoma, Non-Hodgkin
			Preleukemia
			Syndrome
3		More general conditions related to this trial
			Bone Marrow Diseases
			Disease
			Hematologic Diseases
			Immune System Diseases
			Immunoproliferative Disorders
			Lymphatic Diseases
			Lymphoproliferative Disorders
			Myeloproliferative Disorders
			Neoplasms
			Neoplasms by Histologic Type
			Neoplasms by Site
			Pathologic Processes
			Precancerous Conditions
4		Interventions listed in this trial
			StemEx®
5		Sponsors listed in this trial
			Gamida Cell -Teva Joint Venture Ltd.